Int J Clin Pharm Th
-
Int J Clin Pharm Th · Apr 2013
Randomized Controlled Trial Comparative StudyComparative pharmacokinetics and bioavailability of tapentadol following oral administration of immediate- and prolonged-release formulations.
To evaluate the bioavailability and pharmacokinetics of orally administered tapentadol immediate release (IR) compared with tapentadol prolonged release (PR). ⋯ Absolute bioavailability for both tapentadol IR and tapentadol PR was ~ 32% under fasted conditions. Extent of exposure (AUC) for tapentadol PR was very similar to tapentadol IR, whereas Cmax was lower and HVD/MRT longer for the prolonged-release formulation. Overall, the pharmacokinetic characteristics of tapentadol PR enable a twice-daily dosing regimen to be used; such a regimen is expected to improve patient compliance during chronic use.